Effects of Antihypertensive Treatment in HIV Infected Patients: Candesartan Versus Lercanidipine

Università degli Studi dell'Insubria

Status and phase: Unknown; Phase 4

Conditions: Hypertension; HIV Infections

Treatments: Drug: lercanidipine; Drug: candesartan

Study type: Interventional

Funder types: Other

Identifiers

NCT00564057

44758

Details and patient eligibility

About

Human immunodeficiency virus infection and highly active antiretroviral therapy (HAART) are associated with an increased risk of cardiovascular disease: a wide range of alterations in lipid and glucose metabolism has been increasingly recognized in HIV patients treated with HAART. Few data are available on the effects of antihypertensive treatment on cardiac morpho-functional characteristics and metabolic parameters in HIV patients. Aim of the study is to assess the effects of chronic therapy with angiotensin receptor blocker(candesartan)or calcium channel blocker (lercanidipine)on metabolic profile and cardiac remodelling in HIV hypertensive patients.

Enrollment: 30 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HIV infection
• office blood pressure > 140/90 mmHg
• no antihypertensive treatment
• good quality echocardiogram

Exclusion criteria

• cardiovascular diseases
• hypothyroidism
• diabetes
• secondary hypertension
• hepatic and renal failure

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

30 participants in 2 patient groups

1

Experimental group

Description:

candesartan 8-16 mg once daily

Treatment:

Drug: candesartan

2

Active Comparator group

Description:

lercanidipine 10-20 mg once daily

Treatment:

Drug: lercanidipine